Skip to Main Content

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma

Conditions

Melanoma, skin

Phase Pilot

What is the purpose of this trial?

o determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist used alone or in combination with anti-CTLA-4

  • Trial with
    Yale University
  • Start Date
    02/05/2018
  • End Date
    11/30/2019
Trial Image

For more information about this study, contact:

Neta Shanwetter Levit

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    06/22/2018
  • Study HIC
    #2000020477